Cericlamine

Cericlamine (also known as JO-1017) is a drug developed by the pharmaceutical company Janssen Pharmaceutica. It was initially developed as an antidepressant, but its development was discontinued due to lack of efficacy.

History[edit | edit source]

Cericlamine was first developed by Janssen Pharmaceutica, a Belgium-based pharmaceutical company. The drug was initially developed as an antidepressant, but its development was discontinued due to lack of efficacy.

Pharmacology[edit | edit source]

Cericlamine is a reuptake inhibitor and releasing agent of serotonin, norepinephrine, and dopamine, three neurotransmitters known to play key roles in mood regulation. It also acts as a NMDA receptor antagonist, which may contribute to its antidepressant effects.

Clinical trials[edit | edit source]

Cericlamine has undergone several clinical trials for the treatment of major depressive disorder. However, the results of these trials were not promising, and the drug's development was discontinued.

Side effects[edit | edit source]

The most common side effects of cericlamine include nausea, vomiting, dizziness, and insomnia. In rare cases, it can cause serotonin syndrome, a potentially life-threatening condition characterized by agitation, hallucinations, rapid heartbeat, and high body temperature.

See also[edit | edit source]

Cericlamine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.